Business Wire

Sappi Casting and Release Announces New Textures Ahead of interzum 2023

Share

Sappi North America, Inc., a leading producer and supplier of diversified paper, packaging products and dissolving wood pulp, has announced it will showcase seven new and recently launched textures from its Arrio finished surface and Ultracast decorative laminate release paper lines during interzum 2023 in Cologne, Germany from May 9-12, 2023.

Visitors to the Sappi booth (#E-048 in Hall 06.1) will be immersed in a sensory experience with surfacing solutions that demonstrate the impact of how we perceive and experience a variety of materials through natural looking design and our sense of touch. Sappi will feature Arrio, a decorative laminate finished surface that delivers remarkable aesthetics, premium haptics and scratch and fingerprint resistance for high-wear surfaces, including the first textured Arrio, called Saffron. Saffron has an undulating woodgrain with a clean visual appeal and rich, deep valleys paired with a soft touch and a very low gloss surface.

Sappi will also display a decorative laminate texture six-pack and a “bio-lab” that will highlight materials such as bio-based leather alternatives whose aesthetics benefit from the use of Sappi release paper. The six-pack will include these new or recently launched textures:

Matte Stipple: This all-over delicate granular design is inspired by plaster effects in the decorative coatings of walls and ceilings. The matte effect visually softens the look of the texture and adds warmth to the chalky aesthetics. The gritty/sandy haptics create a satisfying touch experience.

Lunaris: With its elevated concrete look, Lunaris expresses the spirit of surface patterns eroded over time, celebrating the beauty of naturally created texture. The matte, porous finish and the gentle touch that characterize Lunaris are central to high-end interiors or environments with calming and restorative effects.

Koa: Koa's curly, wavy pattern is arguably one of the most beautiful woodgrain textures in Sappi’s catalog. The unique figuring, micro-contrast and haptic qualities make it stand out with an incredible optical reflectance that gives an almost 3D quality to the surface.

Kenwood CD Kenwood CD (CD=cross direction) is a modern and sophisticated version of Sappi's popular Kenwood design, aimed at the medium-high-end door market. Kenwood CD features a unique cross-direction orientation ideal for contemporary kitchen and furniture design.

Cayenne: Cayenne is a natural, fresh and trendy wood texture inspired by a refined linear Italian walnut surface. The flow of the dark veins and the softness of the touch are stand-out features. The "wow-effect" of Cayenne is an elegant, smoky matte finish.

Bond: Bond rounds up every elevated laminate collection with the warmth and coziness of a textile finish. The allover matte appeal is enhanced by the subtle sheen of silky threads spreading through the fabric. Bond is symbolic for the beauty of timeless design.

Sappi creates forward-looking products and textures by leveraging state-of-the-art technology from its innovation center in Westbrook, Maine, drawing design inspiration from around the world. Sappi’s extensive library includes a product range of over 70 textures for worktops, kitchen counters and cabinets, flooring, wall paneling and other laminate applications. This wide range of textures, coating and converting capabilities make the company the largest supplier of casting and release papers in the world.

“Texture, haptics, and function are important attributes to the surfaces in our lives, and we’re constantly seeking innovative ways to translate new textures through Arrio finished surfaces and our casting and release papers. We know that what we see and touch shape what we feel,” said Mark Hittie, Director, Release Business Strategy, Sappi North America. “The featured textures in our Ultracast line draw from real-world inspirations to provide authentic, tangible experiences designed with purpose. We’re proud to offer superior textures with unmatched quality and performance for brands that put the consumer experience first.”

To learn more about Sappi, please visit www.sappirelease.com.

About Sappi North America, Inc.

Sappi North America, Inc., headquartered in Boston, is a market leader in converting wood fiber into superior products that customers demand worldwide. Our four diversified businesses – high-quality Graphic Papers, Dissolving Pulp, Packaging, and Specialty Papers deliver premium products and services with consistent quality and reliability. Our high-quality Coated Printing Papers are used for premium magazines, catalogs, books, direct mail and high-end print advertising. We are a leading manufacturer of Dissolving Pulp, which is used in a wide range of products, including textile fibers and household goods. We deliver sustainable Packaging and Specialty Papers for luxury packaging and folding carton applications with our single-ply packaging brands and for the food and label industries with our specialty papers. We are one of the world's leading suppliers of Casting and Release Papers with lines for the automotive, fashion and engineered films industries.

Sappi North America is a subsidiary of Sappi Limited (JSE), a global company headquartered in Johannesburg, South Africa, with more than 12,000 employees and manufacturing operations on three continents in seven countries and customers in over 150 countries. www.sappi.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press

Peter A. Steele
Sappi North America
+1 617 423 5409
Peter.Steele@sappi.com

Christy Reiss
Matter Communications
+1 617 502 6543
Sappi@matternow.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye